2024年5月7日 · Nimodipine is a second-generation 1,4-dihydropyridine calcium channel blocker that was originally approved by the FDA to manage hypertension. Today, nimodipine is …

Nimotop® (nimodipine) is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from …

2024年4月19日 · Detailed Nimodipine dosage information for adults. Includes dosages for Subarachnoid Hemorrhage; plus renal, liver and dialysis adjustments.

Duration: 5 to 14 days for the parenteral product, followed up with oral nimodipine treatment, to complete a 21 day course; The oral dose is 60mg every four hours- i.e. six doses per day; If …

Indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits with subarachnoid hemorrhage from ruptured intracranial berry aneurysms …

2025年1月22日 · If inadvertent IV administration of contents of nimodipine capsules occurs, administer vasopressor agents for cardiovascular support if required for clinically important …

Nimotop concentrated intravenous infusion solution contains ethanol 96% (200 mg/mL), macrogol 400, sodium citrate dihydrate, citric acid and water for injections as excipients. Nimodipine is a …

intravenous infusion solution/h) (about 30μg/kg body weight/h). Patients whose body weight is appreciably below 70kg or who have labile blood pressure should be started with a dose of …

2022年7月1日 · IV infusions should not be used concurrently with Nimodipine oral tablets. Use only the infusion container and the infusion line provided by the manufacturer. Prepare a fresh …

View nimodipine information, including dose, uses, side-effects, pregnancy, breast feeding, contra-indications, important safety information and directions for administration.